{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:46:31Z","timestamp":1782312391644,"version":"3.54.5"},"reference-count":6,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Long-term baricitinib persistence in alopecia areata is not well defined. We performed a retrospective cohort study using hospital-pharmacy dispensing data from 77 patients. Discontinuation was defined as a gap of more than 90\u2005days without medication coverage. The baseline Severity of Alopecia Tool (SALT) score was available for 75 of 77 patients; follow-up SALT data were incomplete. Overall Kaplan\u2013Meier persistence was 91.3% [95% confidence interval (CI) 81.6\u201396.0] at week 52, 75.1% (95% CI 61.0\u201384.7) at week 104, and 68.7% (95% CI 52.8\u201380.2) at week 130. Week 130 persistence was lower in patients with baseline SALT \u2265 95 than in those with SALT &amp;lt; 95 (49.5% vs. 82.3%; exploratory log-rank P = 0.139). Chart-coded discontinuation reasons were heterogeneous and incomplete. Pharmacy-based persistence suggests durable real-world retention beyond 2\u2005years.<\/jats:p>","DOI":"10.1093\/ced\/llag224","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T11:34:00Z","timestamp":1780227240000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-term persistence of baricitinib in alopecia areata: a\u00a0real-world pharmacy-based cohort study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4402-0913","authenticated-orcid":false,"given":"Roberto","family":"Daza-Garc\u00eda","sequence":"first","affiliation":[{"name":"Hospital Universitario Virgen del Roc\u00edo, UGC Dermatolog\u00eda M\u00e9dico-Quir\u00fargica y Venereolog\u00eda , Seville ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-7400","authenticated-orcid":false,"given":"Alonso","family":"Garc\u00eda-N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen del Roc\u00edo, UGC Dermatolog\u00eda M\u00e9dico-Quir\u00fargica y Venereolog\u00eda , Seville ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0640-2200","authenticated-orcid":false,"given":"Antonio","family":"Alcal\u00e1 Ram\u00edrez del Puerto","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen del Roc\u00edo, UGC Dermatolog\u00eda M\u00e9dico-Quir\u00fargica y Venereolog\u00eda , Seville ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6843-5877","authenticated-orcid":false,"given":"Jos\u00e9 Juan","family":"Pereyra-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen del Roc\u00edo, UGC Dermatolog\u00eda M\u00e9dico-Quir\u00fargica y Venereolog\u00eda , Seville ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4023-4174","authenticated-orcid":false,"given":"Rom\u00e1n","family":"Barabash-Neila","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen del Roc\u00edo, UGC Dermatolog\u00eda M\u00e9dico-Quir\u00fargica y Venereolog\u00eda , Seville ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2026062409511901400_llag224-B1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"2026062409511901400_llag224-B2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2026062409511901400_llag224-B3","doi-asserted-by":"crossref","first-page":"2458087","DOI":"10.1080\/09546634.2024.2444494","article-title":"Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study","volume":"36","author":"Vignoli","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"2026062409511901400_llag224-B4","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/1346-8138.17829","article-title":"Long-term real-world outcomes of baricitinib in severe alopecia areata: a 104-week retrospective analysis from a single institute","volume":"52","author":"Wada-Irimada","year":"2025","journal-title":"J Dermatol"},{"key":"2026062409511901400_llag224-B5","doi-asserted-by":"crossref","first-page":"adv13475","DOI":"10.2340\/actadv.v103.13475","article-title":"Drug survival and long-term outcome of tofacitinib in patients with alopecia areata: a retrospective study","volume":"103","author":"Huang","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"2026062409511901400_llag224-B6","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLOS Med"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag224\/68455614\/llag224.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag224\/68455614\/llag224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:51:25Z","timestamp":1782309085000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/advance-article\/doi\/10.1093\/ced\/llag224\/8700155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":6,"URL":"https:\/\/doi.org\/10.1093\/ced\/llag224","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"llag224"}}